Hanwha Files For Korea Approval For Biosimilar Of Amgen’s Enbrel
This article was originally published in PharmAsia News
Executive Summary
Although Hanwha may soon be allowed to sell the biosimilar in Korea, it remains to be seen how its partner Merck will proceed in ex-Korea markets given patent uncertainties.